BRAINTREE, MA and VANCOUVER, BC, Dec. 2, 2014 /CNW/ - Surgical Specialties, Inc. announced today two important additions to its executive management team. Daniel (Dan) Sutherby has joined as Chief Financial Officer (CFO) and Brennan Marilla as Chief Commercial Officer (CCO). The company appointed John Barr as CEO in October 2014.
Dan Sutherby brings experience in both public and private medical device and diagnostic companies. Most recently he spent 6 years at IQuum, a point of care in vitro diagnostic company that was sold earlier this year to Roche for $450 million, including contingent product related milestones. Prior to IQuum, Dan was CFO of Abiomed, Inc. where during his tenure the share price doubled and he led secondary public offerings aggregating over $100 million of proceeds to support the Company's revenue and manufacturing capacity growth initiatives. Prior to Abiomed, Dan spent approximately 8 years at PerkinElmer, Inc. in a variety of senior corporate and operational finance roles as well as investor relations and corporate communications. Dan is a CPA in Massachusetts and has an MS in Finance and BS in Accounting from Bentley University.
Brennan Marilla spent the last four years at Covidien where he held a number of senior management roles in the peripheral and endovascular businesses, including most recently as VP & GM Endovascular, with global P&L responsibility. Prior to Covidien, Brennan spent twelve years at Medtronic in roles of increasing responsibility in sales, sales management, product management and global marketing in their endovascular business. He served his last five years as VP, US Sales Endovascular, where he drove a significant expansion in both sales and profitability for that business including share gains from key competitors. Prior to Medtronic, Brennan spent four years at AngioDynamics in sales leadership positions. Brennan has a BA in Business Management from North Carolina State University.
"We are pleased to add two highly qualified, accomplished and hands on executives in Dan and Brennan," said John Barr, CEO. "Both leaders bring strong track records in medical device and diagnostics companies with demonstrated ability to drive profitable growth. Both Dan and Brennan share my view that Surgical Specialties represents an intriguing opportunity with an established set of products and customer commitment that with enhanced focus and timely execution represent an exciting platform for future growth."
Dan, Brennan and John Barr will be based in the Company's recently opened US headquarters in Braintree, MA.
About Surgical Specialties
Surgical Specialties Corporation develops and manufactures surgical instruments for its own brands (Quill™ knotless tissue closure device, SSC Surgical Suture, Look™ brand sutures, Sharpoint / SSC Microsurgical Knives, BioSentry) and as an original equipment manufacturer for virtually every major medical device company in the US and many more throughout the world. A US based company with a diverse history under its parent company, Angiotech; Surgical Specialties Corporation brings forward a legacy of product excellence through precision manufacturing while maintaining successful global marketing and distribution relationships. Offering one of the most comprehensive portfolios of blades and sutures available, including innovative products such as the Quill™ Knotless Tissue-Closure Device, the company devotes itself to exceeding the needs of the specialty surgery market, having trusted partnerships within dental, ophthalmic, plastic surgery, dermatology, orthopedics, urology, microsurgery, veterinary and trauma specialties. Surgical Specialties Corporation meets the demands of providing real-world customized surgical device solutions. Entrepreneurial spirit combined with a solid history of high-precision design and manufacturing is what makes the company unique. The company's proven track record within the field of precision surgical instrument design and manufacturing underscores not only its efficient methodology, but also its customer-driven, collaborative and ethical values.
SOURCE: Angiotech Pharmaceuticals, Inc.
For further information: For additional information about Surgical Specialties Corporation, please visit our website at www.surgicalspecialties.com.